Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2015 2
2016 3
2017 2
2018 1
2019 1
2020 3
2021 4
2022 7
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Casarrubios M, Provencio M, Nadal E, Insa A, Del Rosario García-Campelo M, Lázaro-Quintela M, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé R, Viñolas N, Barneto Aranda I, Massuti B, Sierra-Rodero B, Martinez-Toledo C, Fernández-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermúdez A. Casarrubios M, et al. Among authors: lazaro quintela m. J Immunother Cancer. 2022 Sep;10(9):e005320. doi: 10.1136/jitc-2022-005320. J Immunother Cancer. 2022. PMID: 36171009 Free PMC article. Clinical Trial.
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, Johne A, Scheele J, Park K, Yang JC; INSIGHT Investigators. Wu YL, et al. Lancet Respir Med. 2020 Nov;8(11):1132-1143. doi: 10.1016/S2213-2600(20)30154-5. Epub 2020 May 29. Lancet Respir Med. 2020. PMID: 32479794 Clinical Trial.
SEOM SOGUG clinical guideline for treatment of kidney cancer (2022).
Méndez-Vidal MJ, Lázaro Quintela M, Lainez-Milagro N, Perez-Valderrama B, Suárez Rodriguez C, Arranz Arija JÁ, Peláez Fernández I, Gallardo Díaz E, Lambea Sorrosal J, González-Del-Alba A. Méndez-Vidal MJ, et al. Among authors: lazaro quintela m. Clin Transl Oncol. 2023 Sep;25(9):2732-2748. doi: 10.1007/s12094-023-03276-5. Epub 2023 Aug 9. Clin Transl Oncol. 2023. PMID: 37556095 Free PMC article.
Prostate cancer perspectives after chaarted: Optimizing treatment sequence.
Estévez SV, Herranz UA, Calvo OF, Afonso Afonso FJ, Couto LS, Quintela ML, Mateos LL, Maciá Escalante S. Estévez SV, et al. Among authors: quintela ml. Crit Rev Oncol Hematol. 2016 Nov;107:119-127. doi: 10.1016/j.critrevonc.2016.08.007. Epub 2016 Aug 21. Crit Rev Oncol Hematol. 2016. PMID: 27823639 Review.
Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
Anido Herranz U, Fernández Calvo O, Afonso Afonso FJ, Rodríguez Martínez de Llano S, Lázaro Quintela M, León Mateos L, Vázquez Estévez S, Antón Aparicio LM. Anido Herranz U, et al. Among authors: lazaro quintela m. Expert Rev Anticancer Ther. 2015 Mar;15(3):339-48. doi: 10.1586/14737140.2015.999045. Epub 2015 Jan 2. Expert Rev Anticancer Ther. 2015. PMID: 25555355 Free article. Review.
Molecular basis of hypertension side effects induced by sunitinib.
Aparicio-Gallego G, Afonso-Afonso FJ, León-Mateos L, Fírvida-Pérez JL, Vázquez-Estévez S, Lázaro-Quintela M, Ramos-Vázquez M, Fernández-Calvo O, Campos-Balea B, Antón-Aparicio LM. Aparicio-Gallego G, et al. Among authors: lazaro quintela m. Anticancer Drugs. 2011 Jan;22(1):1-8. doi: 10.1097/CAD.0b013e3283403806. Anticancer Drugs. 2011. PMID: 20938340 Review.
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.
González Del Alba A, Arranz JÁ, Puente J, Méndez-Vidal MJ, Gallardo E, Grande E, Pérez-Valderrama B, González-Billalabeitia E, Lázaro-Quintela M, Pinto Á, Lainez N, Piulats JM, Esteban E, Maroto Rey JP, García JA, Suárez C. González Del Alba A, et al. Among authors: lazaro quintela m. Crit Rev Oncol Hematol. 2017 May;113:171-190. doi: 10.1016/j.critrevonc.2017.03.010. Epub 2017 Mar 14. Crit Rev Oncol Hematol. 2017. PMID: 28427506 Review.
PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis.
García-González J, Ruiz-Bañobre J, Afonso-Afonso FJ, Amenedo-Gancedo M, Areses-Manrique MDC, Campos-Balea B, Casal-Rubio J, Fernández-Núñez N, Fírvida Pérez JL, Lázaro-Quintela M, Pérez Parente D, Crama L, Ruiz-Gracia P, Santomé-Couto L, León-Mateos L. García-González J, et al. Among authors: lazaro quintela m. J Clin Med. 2020 Jul 3;9(7):2093. doi: 10.3390/jcm9072093. J Clin Med. 2020. PMID: 32635291 Free PMC article. Review.
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis.
González-Larriba JL, Lázaro-Quintela M, Cobo M, Dómine M, Majem M, García-Campelo R. González-Larriba JL, et al. Among authors: lazaro quintela m. Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S21-S34. doi: 10.21037/tlcr.2017.10.03. Transl Lung Cancer Res. 2017. PMID: 29299405 Free PMC article. Review.
23 results